Symptomatic breast cancers diagnosed during the COVID-19 pandemic demonstrated an increase in metastatic disease at presentation along with higher histological grade, more frequent lymphovascular invasion, and differing hormone receptor and histological subtypes when compared to pre-pandemic cases. This evidence concerns the gene NR4A1 and metastatic neoplasm.